Condition

MASLD

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 16 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials16

Recruiting10

Common interventions18

Lead sponsors shown15

Clinical trials

16 shown

RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGMNCT07861191 · 2026-07-27

Hepatic Gene Response to Intravenous Glucose in Obese Patients With and Without MASLD Undergoing Bariatric SurgeryNCT07326865 · 2025-11-12

Effect of Tirzepatide on Markers of MASLD in Patients With ObesityNCT06934642 · 2025-06-30

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled TrialNCT06138821 · 2025-06-24

Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart DiseaseNCT06701968 · 2025-03-20

Digital Early Warning System for Acute Lung Injury in Liver SurgeryNCT07070362 · 2024-11-01

High Fructose Diet, the Gut Microbiome, and Metabolic HealthNCT06329544 · 2024-10-08

Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients With Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) PlacementNCT06814990 · 2024-04-19

Global Research Initiative for Patients Screening on MASHNCT05651724 · 2023-06-30

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver DiseaseNCT04873258 · 2019-09-27

Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · 2026-11-06

NOT_YET_RECRUITING

FIB-4 Cut-Offs for Liver Fibrosis in Obese Endocrinology PatientsNCT07663188 · 2026-09-01

NOT_YET_RECRUITING

Study of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults With Type 1 DiabetesNCT07750210 · 2026-08-22

NOT_YET_RECRUITING

Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIVNCT07640880 · 2026-06-01

NOT_YET_RECRUITING

Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)NCT06845345 · 2025-04-14

ENROLLING_BY_INVITATION

Non-Invasive MASLD Diagnosis & T2D Remission BiomarkersNCT07172997 · 2025-01-01

ACTIVE_NOT_RECRUITING

Common interventions

[6,6-D2]-labeled glucose (intravenous)OTHER1 ALN-CIDEBDRUG1 Bariatric SurgeryPROCEDURE1 Bioimpedence Vector AnalysisDIAGNOSTIC_TEST1 Blood samplesDIAGNOSTIC_TEST1 Cardiac MRIDIAGNOSTIC_TEST1 early time restricted Mediterranean dietOTHER1 EchocardiographyDIAGNOSTIC_TEST1 ESG + lifestyle modificationDEVICE1 FructoseDIETARY_SUPPLEMENT1 glucoseDIETARY_SUPPLEMENT1 Healthy Nordic DietOTHER1 Lifestyle modificationBEHAVIORAL1 MysimbaDRUG1 PlaceboDRUG1 Saline (0.9% sodium chloride infusion)OTHER1 TirzepatideDRUG1 Usual CareBEHAVIORAL1

Leading sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 1 Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis 1 Beijing Tsinghua Chang Gung Hospital 1 Carmen Dietvorst 1 Icahn School of Medicine at Mount Sinai 1 Julius Clinical 1 National University Health System, Singapore 1 Pichamol Jirapinyo, MD, MPH 1 Regeneron Pharmaceuticals 1 Richmond Research Institute 1 Royal College of Surgeons in Ireland - Medical University of Bahrain 1 Sohag University 1 Stephanie Gräger 1 University of New Mexico 1 Uppsala University 1

Trial status mix

RECRUITING10

NOT_YET_RECRUITING4

ACTIVE_NOT_RECRUITING1

ENROLLING_BY_INVITATION1

Phase mix

NA5

EARLY_PHASE11

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.